Oral administration of protein-based biologics faces challenges such as low bioavailability and a short half-life in the gastrointestinal tract. This study focuses on developing a novel encapsulation technique using sodium alginate and chitosan to create nanospheres that efficiently deliver bovine serum albumin, a model protein. Through a combination of single-factor and response surface experiments, optimal preparation conditions were identified, yielding stable nanospheres with high encapsulation rates and small particle sizes. The release of the protein was pH-dependent, with more substantial release under alkaline conditions, resembling the environment of the colon. In vitro safety testing confirmed that the nanospheres had low toxicity and did not induce significant hemolysis or cell death. This approach demonstrates significant potential for enhancing the oral bioavailability of protein-based drugs, overcoming the typical challenges faced by oral drug delivery systems. The developed formulation offers a simple yet effective method for targeted colonic delivery, representing a promising strategy for improving the clinical efficiency of protein biologics.

Breast cancer is a common clinical malignant tumor that seriously threatens women’s physical and mental health. Chemotherapy, as the first choice of breast cancer treatment, has limited its application in the clinic due to problems of poor stability, short half-life, and serious toxic side effects. With the emergence of nanotechnology, inorganic materials to prepare mesoporous silica nanoparticles (MSNs) have been widely used in anti-tumor drug carriers. However, their slow degradation rate limits their application in the biomedical field. Therefore, developing low-toxicity MSNs with good biocompatibility, biodegradability, and rapid release at the tumor site is a key scientific issue to be addressed. Here, we prepared DOX-loaded Ca-Mg-doped MSNs by electrostatic adsorption to obtain Ca-Mg@DOX@MSNs with suitable particle sizes and zeta potential, and the incorporation of calcium and magnesium also led to an increase in the degradation rate under acidic conditions and an accelerated release, which reduced the toxicity of DOX and promoted cellular uptake with good anti-tumor effects. This study provides a new idea for the clinical treatment of breast cancer.

Mesoporous silica nanoparticles (MSNs), an excellent carrier material, have been widely used in tumor therapy as a vector for numerous therapeutic substances to boost therapeutical efficiency and specificity, such as loading them with chemotherapy drugs to improve the efficacy of chemotherapy. Nevertheless, they still face hurdles, such as lack of specificity and poor efficacy of monotherapy. The construction of multifunctional MSNs with excellent therapeutic effects by introducing metal ions has attracted the attention of many researchers. Herein, we demonstrated a calcium doped, chemotherapy drug doxorubicin (Dox) loaded, specific degradation nanoplatform, prepared using the sol–gel method by introducing calcium ions into an MSN framework, which enabled the doped nanoplatform to enhance chemotherapy and activate anti-tumor immune response. As a proof of concept, the doping of Ca²⁺ endowed MSNs with excellent specific degradation and pH responsive drug release, and enabled the synergy of chemotherapy and calcicoptosis. Furthermore, this nanoplatform also effectively elicited immunogenic cell death (ICD) and promoted the maturation of dendritic cells (DCs), realizing the activation of the anti-tumor immune system. The Ca²⁺ doped MSNs (CMSNs), that can activate immune response with specific degradation capability, demonstrate a practical strategy for the effective synergy between chemotherapy and calcicoptosis, providing a new paradigm for promoting chemotherapy-related treatment.

Objectives: To fabricate polysialic acid (PSA)-modified liposomes co-loaded with doxorubicin (DOX) and indocyanine green (ICG) for synergistic chemotherapy and photothermal therapy, and to enhance the anti-cervical cancer efficacy of liposomes via neutrophil targeting. Methods: PSA-DOX/ICG liposomes (PSA-DOX/ICG-Lip) were prepared by microfluidic technology. The physicochemical properties, including drug encapsulation efficiency (EE), loading capacity (LC), particle size, polydispersity index (PDI), zeta potential, and stability, were systematically characterized. The in vitro anti-tumor activity was evaluated using cellular uptake, apoptosis assays, reactive oxygen species (ROS) detection, and a cell scratch test in HeLa and C33a cells. The in vivo therapeutic efficacy was verified using a nude mouse xenograft model of cervical cancer combined with histopathological analysis. Results: Microfluidic preparation yielded PSA-DOX/ICG-Lip with favorable physicochemical properties: the EE and LC of DOX were 96.52 ± 0.43% and 8.70 ± 0.04%, respectively, while those of ICG were 90.72 ± 1.10% and 0.82 ± 0.02%. The average particle size was 92.68 ± 1.14 nm with a PDI of 0.04 and a zeta potential of −9.66 ± 0.46 mV. The liposomes maintained good stability in terms of EE, particle size, PDI, and zeta potential after 28 days of storage at 4 °C and room temperature, with PSA modification significantly reducing the drug leakage rate. In vitro drug release studies showed that 808 nm laser irradiation triggered a significant increase in drug release from the liposomes. ICG encapsulated in liposomes mediated localized photothermal heating, and PSA targeting precisely confined the therapeutic effect to the tumor site, minimizing damage to adjacent normal tissues. In vitro experiments demonstrated that PSA-DOX/ICG-Lip, combined with laser irradiation, significantly enhanced cellular uptake, elevated intracellular ROS levels, inhibited cancer cell migration, and induced apoptosis. In vivo studies confirmed that this formulation markedly suppressed tumor growth in nude mice, with a tumor inhibition rate of 81.5%, and exhibited good biocompatibility without obvious organ toxicity. Conclusions: The microfluidically prepared PSA-DOX/ICG-Lip possesses high drug encapsulation efficiency, uniform particle size, good stability and sustained drug release properties. It can efficiently convert light energy into thermal energy, target neutrophils to enhance the affinity for cervical cancer cells, and exert a synergistic anti-tumor effect via the combination of chemotherapy and photothermal therapy, which provides a promising nanoplatform for the precise treatment of cervical cancer.